anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a lipstick composition excellent in feeling of use, makeup durability and preventing effects on color staining. CONSTITUTION: This lipstick composition contains (A) a volatile silicone oil, e.g. octamethylcyclotetrasiloxane or decamethylcyclopentaslloxane, (B) dimethylsilylated silicic acid anhydride and/or silicone-treated silicic acid anhydride and (C) a powder usually used in a makeup cosmetic. The amounts of the ingredients based on 100 pts.wt. cosmetic are 20-70 pts.wt. ingredient (A), 0.1-10 pts.wt. ingredient (B) and 0.1-20 pts.wt. ingredient (C). The dimethylsilylated silicic acid anhydride is obtained by carrying out the vapor treatment of the surface of silicic acid anhydride with, e.g. dimethylchlorosilane. The silicone-treated silicic acid anhydride is obtained by carrying out the coating treatment of silicic acid anhydride with dimethylpolysiloxane, methylhydrogenpolysiloxane or cyclic silicones. Furthermore, a water-soluble salt of alginic acid and a bi- or a trivalent metallic salt in an amount of 0.1-5 pts.wt. total amount of both are preferably contained in the composition.
The invention discloses an extraction method of divaricate saposhnikovia root volatile oil, which comprises the following steps: drying and crushing the divaricate saposhnikovia root medicinal material, and sieving the divaricate saposhnikovia root medicinal material with a 18-mesh sieve. Drying at 60 deg.C for 4 hr, precisely weighing 100g (to 0.0001g), and placing into extraction kettle. Heating the extraction kettle, the separation kettle I and the separation kettle II, and pressurizing the system by a high-pressure pump when the temperature of the extraction kettle, the separation kettle I and the separation kettle II reaches 35-40 ℃. When the pressure of the extraction kettle, the separation kettle I and the separation kettle II reaches 15-35MPa, the flow of CO2 is adjusted, and the constant temperature and the constant pressure are kept. And after the selected extraction time is reached, discharging from discharge ports of the separation kettle I and the separation kettle II, and respectively collecting and storing the extracts. Separating the extract with chromatography column. The extraction method of the invention is simple and easy to implement, has high yield, does not need a large amount of organic solvents, is safe and nontoxic, and is suitable for industrial production.
HIV related premature cellular aging and declines in mitochondrial function are closely linked. Dysfunctional mitochondria generate higher levels of reactive oxygen species (ROS) and provide less ATP supply cellular energy. Impaired turnover of damaged mitochondria leads to gradual but progressive decline in energy metabolism, increases in muscle fibrosis and clinically apparent weakness. The Renin Angiotensin System (RAS) is a central hormonal system that contributes to mitochondrial dysfunction and impacts both lifespan and function across multiple organ systems. Deletion of the angiotensin type 1 receptor (AT1R) results in a 25-30% extension of lifespan in mouse models, partly through increasing mitochondrial numbers. Blocking of AT1R reduces a number of age-related morbidities in mice, and in human studies. A plethora of data implicates RAS modulation in marked effects on fitness, frailty and beneficial responses to exercise in older adults. Despite this, there are virtually no data examining RAS biology in HIV+ vs. age-matched HIVsubjects, no data of RAS in relation to key HIV-specific variables (duration of HIV, treatment history, immune markers), and no data examining the effects of blocking AT1R on physical function in HIV infected subjects. In this study, we will examine the RAS and its contribution to premature mitochondrial failure in HIV patients. We will begin to fill this void by enrolling 40 HIV+ subjects in a randomized, double-blinded, placebo controlled pilot study of treatment with AT1R blocker to determine the feasibility of a larger trial, estimate effect size, assess the correlation of angiotensin receptor (AR) expression in peripheral blood cells and muscle cells, and the association of AR expression with physical function measures and immunity.
Telmisartan

Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ARBs, including telmisartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. The antihypertensive effect of ARBs may be attenuated by NSAIDs. Therefore, monitor renal function and blood pressure periodically in patients receiving telmisartan and hydrochlorothiazide tablets and NSAIDs.

Hydrochlorothiazide

Administration of a non-steroidal anti-inflammatory agent, including a selective COX-2 inhibitor, can reduce the diuretic, natriuretic, and antihypertensive effects of diuretics. Therefore, when telmisartan and hydrochlorothiazide tablets and non- steroidal anti-inflammatory agents including selective COX-2 inhibitors are used concomitantly, observe closely to determine if the desired effect of the diuretic is obtained.
PROBLEM TO BE SOLVED: To obtain a sunscreen agent inhibiting to remove fats from skins and hardly giving loads to the skins by compounding an inorganic pigment and a non-volatile oil. SOLUTION: This sunscreen agent, preferably a cosmetic foundation, contains (A) an inorganic pigment and (B) a nonvolatile oil in an amount of >=70 wt.% based on the total oil-absorbing amount of the pigment. The component A is necessary to have a UV light-absorbing ability, includes titanium dioxide and zinc oxide, and preferably has a particle diameter of 10-100 nm. The pigment may contain a pigment except the component A, such as organic powder such as a colorant or resin powder, or an extender pigment. The component B includes cetyl alcohol and isostearyl alcohol. The pigment is preferably compounded in an amount of 3-40 wt.% based on the total amount of the production, and the component A in the pigments is preferably compounded in an amount of 5-35 wt.%.  The sunscreen agent may further be compounded with an antioxidant (for example, tocopherol), a solvent (for example, purified water or ethanol), etc.
PURPOSE:To obtain a composition for hepatic disease remedy having improved elution properties, excellent durability and high bio-availability, by dissolving tritoqualine and a water-soluble high polymer in an organic solvent and coprecipitating. CONSTITUTION:Tritoqualine shown by the formula and a waters-soluble high polymer are dissolved in an organic solvent (especially preferably methanol or chloroform), then the solvent is removed and tritoqualine and the water-soluble high polymer are coprecipitated to give a tritoqualine composition. Polyvinyl pyrrolidone, polyethylene glycol, hydroxypropylmethyl cellulose, etc., are preferably as the water-soluble high polymer and the amount of the water-soluble high polymer used is 1-10pts.wt., preferably 2-6pts.wt. based on 1pt.wt. tritoqualine. As a practical method, preferably the raw material two components are dissolved in the organic solvent, the solvent is removed at normal temperature or under heating or optionally in vacuum and the two components are coprecipitated.
Recommended Dosage in Adults

The recommended Duloxetine delayed-release capsules dosage is 60 mg once daily in adults with fibromyalgia. Begin treatment at 30 mg once daily for 1 week, to allow patients to adjust to Duloxetine delayed-release capsules before increasing to 60 mg once daily. Some patients may respond to the starting dosage. There is no evidence that dosages greater than 60 mg/day confer additional benefit, even in patients who do not respond to a 60 mg/day dosage, and higher dosages were associated with a higher rate of adverse reactions.

Additional pediatric use information is approved for Eli Lilly and Company, Inc.'s CYMBALTA (duloxetine) delayed-release capsules. However, due to Eli Lilly and Company Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Methylcantharidimide tablets( 75mg po tid) is administered before first TACE 3 days and taken continuously after TACE treatment. Every 6 weeks is a cycle.
A single sample group . Anthropometric measurements were taken at the beginning of all patients. Yogurt with probiotic added to medical nutrition therapy was applied for 2 weeks.Anthropometric measurements were taken at the beginning of all patients. Yogurt with probiotic added to medical nutrition therapy was applied for 2 weeks. At the end of each week, food consumption records and scales were applied. During the wash out period, all patients were asked to comply with their diet only. After the wash out period, a different diet was started and the same procedures were repeated.During the wash out period, all patients were asked to comply with their diet only. After the wash out period, a different diet (with the addition of probiotic yogurt) was changed and the same procedures were repeated.
The INK4A (MTS1, CDKN2) gene encodes a specific inhibitor (InK4a-p16) of the cyclin D-dependent kinases CDK4 and CDK6. InK4a-p16 can block these kinases from phosphorylating the retinoblastoma protein (pRb), preventing exit from the G1 phase of the cell cycle. Deletions and mutations involving the gene encoding InK4a-p16, InK4A, occur frequently in cancer cells, implying that INK4a-p16, like pRb, suppresses tumor formulation. However, a completely unrelated protein (ARF-p19) arises in major part from an alternative reading frame of the mouse INK4A gene. Expression of an ARF-p19 cDNA (SEQ ID NO:1) in rodent fibroplasts induces both G1 and G2 phase arrest. Economical reutilization of protein coding sequences in this manner is without precedent in mammalian genomes, and the unitary inheritance of INK4a-p16 and ARF-p19 may reflect a dual requirement for both proteins in cell cycle control.
Lysophosphatidylcholine (LPC) is immunomodulatory in nonruminants; however, the actions of LPC on immunity in cattle are undefined. Our objective was to study the effects of LPC administration on measures of immunity, liver health, and growth in calves. Healthy Holstein heifer calves (n = 46; age 7 ± 3 d) were randomly assigned to 1 of 4 treatments (n = 10 to 11 calves/treatment): a milk replacer diet unsupplemented with lecithin in the absence (CON) or presence of subcutaneously (s.c.) administered mixed (mLPC; 69% LPC-16:0, 25% LPC-18:0, 6% other) or pure LPC (pLPC; 99% LPC-18:0), or a milk replacer diet supplemented with 3% lecithin enriched in lysophospholipids containing LPC in the absence of s.c.-administered LPC (LYSO) for 5 wk. Calves received 5 s.c. injections of vehicle (10 mL of phosphate-buffered saline containing 20 mg of bovine serum albumin/mL; CON and LYSO) or vehicle containing mLPC or pLPC to provide 10 mg of total LPC per kilogram of BW per injection every 12 h during wk 2 of life. Calves were fed a milk replacer containing 27% crude protein and 24% fat at 1.75% of BW per day (dry matter basis) until wk 6 of life (start of weaning). Starter grain and water were provided ad libitum. Body measurements were recorded weekly, and clinical observations were recorded daily. Blood samples were collected weekly before morning feeding and at 0, 5, and 10 h, relative to the final s.c. injection of vehicle or LPC. Data were analyzed using a mixed model, with repeated measures including fixed effects of treatment, time, and their interaction. Dunnett's test was used to compare treatments to CON. Peak rectal temperatures were higher in mLPC or pLPC, relative to CON. Plasma LPC concentrations were greater in mLPC and LYSO calves 5 h and 10 h after the final injection, relative to CON. Calves receiving mLPC and pLPC also had higher circulating serum amyloid A concentrations, relative to CON. Calves receiving mLPC had greater serum aspartate aminotransferase, γ-glutamyltransferase, and glutamate dehydrogenase concentrations, relative to CON. Calves provided mLPC experienced lower average daily gain (ADG) after weaning, relative to CON. The LYSO treatment did not modify rectal temperatures, ADG, or measures of liver health, relative to CON. We conclude that LPC administered as s.c. injections induced an acute febrile response, modified measures of liver and immune function, and impaired growth in calves.
OBJECTIVES: Fluoroscopy has significantly improved lead placement and decreased surgical time for implantable sacral neuromodulation (SNM). There is a paucity of data regarding radiation and safety of fluoroscopy during SNM procedures. Our study aims to characterize fluoroscopy time and dose used during SNM surgery across multiple institutions and assess for predictors of increased fluoroscopy time and radiation dose.
METHODS: Electronic medical records were queried for SNM procedures (Stage 1 and full implant) from 2016 to 2021 at four academic institutions. Demographic, clinical, and intraoperative data were collected, including fluoroscopy time and radiation dose in milligray (mGy). The data were entered into a centralized REDCap database. Univariate and multivariate analysis were performed to assess for predictive factors using STATA/BE 17.0.
RESULTS: A total of 664 procedures were performed across four institutions. Of these, 363 (54.6%) procedures had complete fluoroscopy details recorded. Mean surgical time was 58.8 min. Of all procedures, 79.6% were performed by Female Pelvic Medicine and Reconstructive Surgery specialists. There was significant variability in fluoroscopy time and dose based on surgical specialty and institution. Most surgeons (76.4%) were considered "low volume" implanters. In a multivariate analysis, bilateral finder needle testing, surgical indication, surgeon volume, and institution significantly predicted increased fluoroscopy time and radiation dose (p < 0.05).
CONCLUSIONS: There is significant variability in fluoroscopy time and radiation dose utilized during SNM procedures, with differences across institutions, surgeons, and subspecialties. Increased radiation exposure can have harmful impacts on the surgical team and patient. These findings demonstrate the need for standardized fluoroscopy use during SNM procedures.
The present disclosure specifically relates to a composition for inhibiting respiratory viruses and a method for preventing and treating a respiratory virus. Respiratory viral infections are extremely common clinically, yet the current therapeutic drugs for viral infections cannot meet the treatment needs. The present disclosure provides an inhalant for inhibiting respiratory viruses and adopts a method of inhaling high-temperature acetic acid steam for prevention and treatment. Acetic acid in the high-temperature steam can release hydrogen ions to inactivate viruses in the respiratory tract, so as to prevent the onset of the disease and provide a therapeutic effect. In addition, the composition can be used to inhibit fungi and bacteria  in vitro  and prevent skin diseases and respiratory diseases caused by bacteria and fungi. The prevention and treatment method of the present disclosure is easy to implement and has low costs and important clinical application value.
ZYTIGA may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition [see Clinical Pharmacology (12.1)] . Monitor patients for hypertension, hypokalemia, and fluid retention at least once a month. Control hypertension and correct hypokalemia before and during treatment with ZYTIGA. 

In the combined data from 4 placebo-controlled trials using prednisone 5 mg twice daily in combination with 1,000 mg abiraterone acetate daily, grades 3–4 hypokalemia were detected in 4% of patients on the ZYTIGA arm and 2% of patients on the placebo arm. Grades 3–4 hypertension were observed in 2% of patients each arm and grades 3–4 fluid retention in 1% of patients each arm.

In LATITUDE (a randomized placebo-controlled, multicenter clinical trial), which used prednisone 5 mg daily in combination with 1,000 mg abiraterone acetate daily, grades 3–4 hypokalemia were detected in 10% of patients on the ZYTIGA arm and 1% of patients on the placebo arm, grades 3–4 hypertension were observed in 20% of patients on the ZYTIGA arm and 10% of patients on the placebo arm. Grades 3–4 fluid retention occurred in 1% of patients each arm [see Adverse Reactions (6)] . 

Closely monitor patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia or fluid retention, such as those with heart failure, recent myocardial infarction, cardiovascular disease, or ventricular arrhythmia. In postmarketing experience, QT prolongation and Torsades de Pointes have been observed in patients who develop hypokalemia while taking ZYTIGA.

The safety of ZYTIGA in patients with left ventricular ejection fraction <50% or New York Heart Association (NYHA) Class III or IV heart failure (in COU-AA-301) or NYHA Class II to IV heart failure (in COU-AA-302 and LATITUDE) has not been established because these patients were excluded from these randomized clinical trials [see Clinical Studies (14)] .
This study leverages two evidence-based interventions (EBIs) that have been culturally-adapted for the target population and have previously achieved clinically-relevant weight loss and other clinical outcomes (educational group weight loss intervention) along with improvements in diet and physical activity (home gardening intervention). Combining these EBIs addresses multiple domains (behavioral, personal environment, sociocultural) and levels (individual, interpersonal, community) of influence on risk factors for obesity and other cardiometabolic diseases prevalent in the Deep South. These interventions, delivered by local lay staff and non-academic partners, have a high potential for sustainability; however, there is a need to further evaluate the external validity and implementation-related barriers and facilitators to maximize reach, adoption and implementation. The investigators will employ a pragmatic, multilevel, cluster-randomized, type 1 hybrid effectiveness-implementation trial. A total of 264 Black women (age ≥ 30 years) with overweight or obesity and pre-diabetic or hypertensive from 12 rural counties (6 Alabama, 6 Mississippi) will receive either the combined educational group weight loss intervention plus a home gardening intervention or the educational group weight loss classes alone. The specific aims are to compare interventions on: (1) primary outcomes related to implementation effectiveness (reach, adoption, maintenance of health behaviors), (2) secondary outcomes on clinical effectiveness, and (3) cost effectiveness. Findings will inform discussions with coalition partners to achieve our long-term goal of widely disseminating and sustaining multi-level interventions to reduce the multiple chronic disease burden and health disparities in the Deep South.
The present invention discloses a manufacturing method of a cosmetic impregnated material and a cosmetic impregnated material. Coating layers are provided on the surface and back surface of an impregnated material body, respectively, and a first urethane resin coating layer and a second urethane resin coating layer are attached to the surface and back surface of the impregnated material body, respectively, and then cured to harden one end of the first urethane resin coating layer and one end of the second urethane resin coating layer in a state of being naturally impregnated into the inside of the surface and back surface of the impregnated material body, respectively, so no glue is required. Since fixation between the first and second urethane resin coating layers and the impregnated material body is greatly improved, it is possible to prevent the first urethane resin coating layer and the second urethane resin coating layer from being separated from the impregnated material body during use, so elastic action as well as deterioration prevention of cosmetics can be continuously achieved. Since cosmetics impregnated by the transparent urethane coating layer appear bright, the color of the cosmetics impregnated in the impregnated material body is exposed to the outside as it is, so the color of the cosmetics impregnated can be easily grasped with the naked eye. The inner diameter of a plurality of perforated discharge holes is 3.5 to 5.0 mm to control the discharge of cosmetics and to prevent excessive discharge of cosmetics. The cosmetics can be used for a long time by preventing corrosion of the impregnated material body as well as deterioration of the impregnated cosmetics and evaporation of the cosmetics.
KCNMA1 located on chromosome 10q22.3, encodes the pore-forming α subunit of the 'Big K+' (BK) large conductance calcium and voltage-activated K + channel. Numerous evidence suggests the functional BK channel alterations produced by different KCNMA1 alleles may associate with different symptoms, such as paroxysmal non kinesigenic dyskinesia with gain of function and ataxia with loss of function. Functional classifications revealed two major patterns, gain of function and loss of function effects on channel properties in different cell lines. In the literature, two mutations have been shown to confer gain of function properties to BK channels: D434G and N995S. In this study, we report the functional characterization of a variant which was previously reported the whole exome sequencing revealed bi-allelic nonsense variation of the cytoplasmic domain of calcium-activated potassium channel subunit alpha-1 protein. To detect functional consequences of the variation, we parallely conducted two independent approaches. One is immunostaining using and the other one is electrophysiological recording using patch-clamp on wild-type and R458X mutant cells to detect the differences between wild-type and the mutant cells. We detected the gain of function effect for the mutation (NM_001161352.1 (ENST00000286628.8):c.1372C > T;Arg458*) using two parallel approaches. According to the result we found, the reported mutation causes the loss of function in the cell. It should be noted that in future studies, it can be thought that the functions of genes associated with channelopathies may have a dual effect such as loss and gain.
The present invention describes a method for the impregnation of a drug or a drug composition into ophthalmic articles, in order to prepare drug sustained release systems mainly for the treatment of glaucoma and other eye diseases. Ophthalmic articles can be for example contact lenses.      The drug or drug composition is dissolved in a compressed fluid, or mixture of compressed fluids, in a liquid, sub-critical liquid, gaseous or supercritical state. Co-solvents can be added to increase drug solubility in the compressed fluids. The mixture is subsequently contacted with the ophthalmic article. This process can be done in a single step or in a double step manner. The impregnation can be carried out in finished or semi-finished ophthalmic articles.